Robotic Natural Orifice Specimen Extraction Surgery Compared to Robotic Assisted Surgery for Median Rectal Cancer
the First Affiliated Hospital of Nanchang University
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330000
- The First Affiliated Hospital of Nanchang University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The age is more than 18 years old and less than or equal to 85 years old
- Eastern Cooperative Oncology Group score ≤2
- Preoperative pathological diagnosis of rectal adenocarcinoma
- cT1-3NxM0 median rectal cancer defined by preoperative contrast-enhanced MRI
- The maximum diameter of tumor ≤5cm on preoperative enhanced MRI
- The body can tolerate the operation and sign the informed consent
Exclusion Criteria:
- multiple primary colorectal cancer
- recurrent rectal cancer
- preoperative neoadjuvant chemoradiotherapy
- complicated with intestinal obstruction or intestinal bleeding requiring emergency surgery
- previous anal surgery history
- BMI≥30kg/m2
- severe mental illness
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: robotic natural orifice specimen extraction surgery for middle rectal cancer
After the body is free, the tumor segment of the bowel is pulled out through the anus.
Excise the tumor segment of the colon outside the anus.
|
After the rectum and its mesorectum were dissociated, the rectum was transected at 2 cm below the tumor by using a linear stapler.
Then the rectal stump was incised and disinfected with iodophor, the protective sleeve was placed into the abdominal cavity through the assistant hole.
An assistant delivered oval forceps into the pelvic cavity through the anus and used oval forceps to grip one end of the protective sleeve.
Then slowly pulled out the protective sleeve.
Eventually, one end of the protective sleeve was placed inside the abdominal cavity and the other outside the anus, completely covering the rectal stump and the perianal area.
Tumor was pulled out of the rectal stump, then the colon was then disconnected at 10 cm above the tumor.
The anvil was placed into the stump of the sigmoid colon and disinfected with iodophor, and then the anvil was delivered into the abdominal cavity.
Place a circular stapler through the anus for end-to-end anastomosis of the rectum and sigmoid colon.
|
|
Sham Comparator: robotic transabdominal specimen extraction surgery for middle rectal cancer
After internal mobilization, the tumor segment of the bowel was removed through an abdominal incision.
Excise the tumor segment of the bowel outside the incision.
|
After the rectum and its mesorectum were dissociated, the rectum was transected at 2 cm below the tumor by using a linear stapler.
Take a 6cm incision through the rectus abdominis muscle in the lower left abdomen and place an incision protective cover.
Cut off the intestinal tube 10cm from the upper edge of the tumor and place a stapler base.
The rectal stump was sutured with purse-string suture.
Place a circular stapler through the anus for end-to-end anastomosis of the rectum and sigmoid colon.
After completion of digestive tract reconstruction.
The pelvic and abdominal cavities were washed repeatedly with normal saline until there were no blood remained.
Close the abdominal cavity layer by layer.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The rate of all complications
Time Frame: 1 months after surgery
|
incidence rate
|
1 months after surgery
|
|
The rate of all complications (Clavien-Dindo grade ≥ III )
Time Frame: 1 months after surgery
|
incidence rate
|
1 months after surgery
|
|
The rate of anastomotic complications
Time Frame: 1 months after surgery
|
Anastomotic leakage and anastomotic bleeding
|
1 months after surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
operative time
Time Frame: Intraoperative
|
minutes
|
Intraoperative
|
|
estimation of blood loss
Time Frame: Intraoperative
|
milliliters
|
Intraoperative
|
|
postoperative hospital stay
Time Frame: 1 day after operation
|
days
|
1 day after operation
|
|
visual analogue pain score
Time Frame: 1 weeks after surgery
|
score
|
1 weeks after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: shanping Ye, The First Affiliated Hospital of Nanchang University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IIT2024013
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.